4.7 Review

Genetic Variants at Chromosome 9p21 and Risk of First Versus Subsequent Coronary Heart Disease Events

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 63, Issue 21, Pages 2234-2245

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.01.065

Keywords

coronary heart disease; genomics; incident; subsequent; 9p21

Funding

  1. National Institute for Health Research (NIHR) Clinical Lectureship
  2. Netherlands Organization for Health Research and Development (ZonMw) [90700342]
  3. UCL NIHR Biomedical Research Centre
  4. National Institutes of Health at Emory University [UL1 RR025008]
  5. NIHR [RP-PG-0407-10314]
  6. Medical Research Council (MRC) Prognosis Research Strategy (PROGRESS) Partnership [G0902393/99558]
  7. U.K. MRC Population Health Scientist Fellowship [G0802432]
  8. Medical Research Council [G0802432, MR/K006584/1] Funding Source: researchfish
  9. National Institute for Health Research [RP-PG-0407-10314, CL-2011-11-003] Funding Source: researchfish
  10. MRC [G0802432] Funding Source: UKRI

Ask authors/readers for more resources

Objectives The purpose of this analysis was to compare the association between variants at the chromosome 9p21 locus (Ch9p21) and risk of first versus subsequent coronary heart disease (CHD) events through systematic review and meta-analysis. Background Ch9p21 is a recognized risk factor for a first CHD event. However, its association with risk of subsequent events in patients with established CHD is less clear. Methods We searched PubMed and EMBASE for prospective studies reporting association of Ch9p21 with incident CHD events and extracted information on cohort type (individuals without prior CHD or individuals with established CHD) and effect estimates for risk of events. Results We identified 31 cohorts reporting on 193,372 individuals. Among the 16 cohorts of individuals without prior CHD (n = 168,209), there were 15,664 first CHD events. Ch9p21 was associated with a pooled hazard ratio (HR) of a first event of 1.19 (95% confidence interval: 1.17 to 1.22) per risk allele. In individuals with established CHD (n 25,163), there were 4,436 subsequent events providing >99% and 91% power to detect a per-allele HR of 1.19 or 1.10, respectively. The pooled HR for subsequent events was 1.01 (95% confidence interval: 0.97 to 1.06) per risk allele. There was strong evidence of heterogeneity between the effect estimates for first and subsequent events (p value for heterogeneity = 5.6 X 10(-11)). We found no evidence for biases to account for these findings. Conclusions Ch9p21 shows differential association with risk of first versus subsequent CHD events. This has implications for genetic risk prediction in patients with established CHD and for mechanistic understanding of how Ch9p21 influences risk of CHD. (J Am Coll Cardiol 2014; 63: 2234-45) (C) 2014 by the American College of Cardiology Foundation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Longitudinal profile of circulating endothelial cells in post-acute coronary syndrome patients

Marie de Bakker, Jaco Kraan, K. Martijn Akkerhuis, Rohit Oemrawsingh, Folkert W. Asselbergs, Imo Hoefer, Isabella Kardys, Eric Boersma

Summary: Patients who have had acute coronary syndrome (ACS) are at risk of a recurrent event, but their level of risk varies. Longitudinal measurements of circulating endothelial cells (CECs) have the potential to improve individual risk assessment.

BIOMARKERS (2023)

Article Mathematical & Computational Biology

LoFTK: a framework for fully automated calculation of predicted Loss-of-Function variants and genes

Abdulrahman Alasiri, Konrad J. J. Karczewski, Brian Cole, Bao-Li Loza, Jason H. H. Moore, Sander W. W. van der Laan, Folkert W. W. Asselbergs, Brendan J. J. Keating, Jessica van Setten

Summary: Loss-of-Function (LoF) variants in human genes have a significant impact on clinical phenotypes and are frequently found in healthy individuals' genomes. The Loss-of-Function ToolKit (LoFTK) has been developed to efficiently predict LoF variants from genotyped and sequenced genomes, allowing the identification of inactive genes with 1 or 2 copies and the discovery of potential therapeutic targets.

BIODATA MINING (2023)

Review Cardiac & Cardiovascular Systems

Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies

Karen R. Gaar-Humphreys, Alyssa Brink, Mark Wekking, Folkert W. Asselbergs, Frank G. van Steenbeek, Magdalena Harakalova, Jiayi Pei

Summary: Inherited cardiomyopathies, caused by pathological genetic variants, encompass various types of heart diseases. Next-generation sequencing has facilitated the identification of numerous genetic variants as pathological ones, but there is variation in disease penetrance among mutated genes, leading to a complex genotype-phenotype relationship. Previous studies have highlighted disrupted metabolism and metabolic adaptations in inherited cardiomyopathies, particularly in lipid metabolism. This mini-review discusses the metabolic changes associated with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), the most common subtypes, and emphasizes the potential of PPARA-targeting drugs as fatty acid oxidation modulators in treating inherited cardiomyopathies.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Sex differences in the generalizability of randomized clinical trials in heart failure with reduced ejection fraction

Megan Schroeder, Yvonne Mei Fong Lim, Gianluigi Savarese, Kiliana Suzart-Woischnik, Claire Baudier, Tomasz Dyszynski, Ilonca Vaartjes, Marinus J. C. Eijkemans, Alicia Uijl, Ronald Herrera, Eleni Vradi, Jasper J. Brugts, Hans-Peter Brunner-La Rocca, Vanessa Blanc-Guillemaud, Sandra Waechter, Fabrice Couvelard, Benoit Tyl, Samuel Fatoba, Arno W. Hoes, Lars H. Lund, Christoph Gerlinger, Folkert W. Asselbergs, Diederick E. Grobbee, Maureen Cronin, Stefan Koudstaal

Summary: To understand the impact of sex differences on the generalizability of randomized clinical trials (RCTs) in heart failure (HF) patients, a comparison was made between RCTs and HF observational registries stratified by sex. The results showed that there were no differences in trial enrollment between males and females, but female trial participants had lower mortality rates while male trial participants had higher cardiovascular mortality rates.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

Article Medicine, General & Internal

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

Jasper J. Brugts, Sumant P. Radhoe, Pascal R. D. Clephas, Dilan Aydin, Marco W. F. van Gent, Mariusz K. Szymanski, Michiel Rienstra, Mieke H. van den Heuvel, Carlos A. da Fonseca, Gerard C. M. Linssen, C. Jan Willem Borleffs, Eric Boersma, Folkert W. Asselbergs, Arend Mosterd, Hans-Peter Brunner-La Rocca, Rudolf A. de Boer

Summary: The MONITOR-HF trial conducted in the Netherlands examined the impact of haemodynamic monitoring on quality of life and heart failure hospitalization in patients with heart failure. The study found that haemodynamic monitoring significantly improved patients' quality of life and reduced heart failure hospitalizations.

LANCET (2023)

Article Cardiac & Cardiovascular Systems

Identifying patients at risk: multi-centre comparison of HeartMate 3 and HeartWare left ventricular assist devices

Lieke Numan, Daniel Zimpfer, Osnat Itzhaki Ben Zadok, Emmeke Aarts, Michiel Morshuis, Sabina P. W. Guenther, Julia Riebandt, Dominik Wiedemann, Faiz Z. Ramjankhan, Anne-Marie Oppelaar, Tuvia Ben-Gal, Binyamin Ben-Avraham, Folkert W. Asselbergs, Rene Schramm, Linda W. Van Laake

Summary: This study compared the outcomes of patients using HeartWare (HVAD) and HeartMate 3 (HM3), and found that HM3 patients had better survival rates and lower incidence of heart failure. The results suggest that prophylactic exchange to HM3 is necessary for HVAD patients.

ESC HEART FAILURE (2023)

Letter Public, Environmental & Occupational Health

CHALLENGES IN ESTIMATING THE EFFECTIVENESS OF 2 DOSES OF COVID-19 VACCINE BEYOND 6 MONTHS IN ENGLAND

Elsie M. F. Horne, William J. Hulme, Ruth H. Keogh, Tom M. Palmer, Elizabeth J. Williamson, Edward P. K. Parker, Venexia M. Walker, Rochelle Knight, Yinghui Wei, Kurt Taylor, Louis Fisher, Jessica Morley, Amir Mehrkar, Iain Dillingham, Sebastian Bacon, Ben Goldacre, Jonathan A. C. Sterne

Summary: Understanding how the effectiveness of COVID-19 vaccines changes over time and in response to new variants is crucial for scheduling subsequent doses. Previous research has shown that vaccine effectiveness decreases in a log-linear manner over time and remains consistent across different risk-based subgroups. To further investigate the waning effectiveness beyond 26 weeks and in the era of the Omicron variant, the follow-up period was extended to the earliest of 50 weeks after the second dose or March 31, 2022.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2023)

Article Medicine, General & Internal

Triangulating evidence from observational and Mendelian randomization studies of ketone bodies for cognitive performance

Wichanon Sae-jie, Suangsuda Supasai, Mika Kivimaki, Jackie F. Price, Andrew Wong, Meena Kumari, Jorgen Engmann, Tina Shah, Amand F. Schmidt, Tom R. Gaunt, Aroon Hingorani, Pimphen Charoen

Summary: This study uses triangulation of evidence from observational and Mendelian randomization studies to investigate the association and causation between ketone bodies and cognitive function. The results suggest that 3-beta-hydroxybutyrate (BOHBUT), the most abundant ketone metabolite, has a beneficial effect on cognitive performance and may delay cognitive impairment and reduce the risk of Alzheimer's disease.

BMC MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Monitoring of Myocardial Involvement in Early Arrhythmogenic Right Ventricular Cardiomyopathy Across the Age Spectrum

Feddo P. Kirkels, Nick van Osta, Christine Rootwelt-Norberg, Monica Chivulescu, Tim van Loon, Eivind W. Aabel, Anna I. Castrini, Oyvind H. Lie, Folkert W. Asselbergs, Tammo Delhaas, Maarten J. Cramer, Arco J. Teske, Kristina H. Haugaa, Joost Lumens

Summary: This study aims to assess the need for age-tailoring of follow-up protocols in early ARVC by evaluating myocardial disease progression in different age groups.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Genetics & Heredity

Multi-ancestry genome-wide study identifies effector genes and druggable pathways for coronary artery calcification

Maryam Kavousi, Maxime M. Bos, Hanna J. Barnes, Christian L. Lino Cardenas, Doris Wong, Haojie Lu, Chani J. Hodonsky, Lennart P. L. Landsmeer, Adam W. Turner, Minjung Kho, Natalie R. Hasbani, Paul S. de Vries, Donald W. Bowden, Sandesh Chopade, Joris Deelen, Ernest Diez Benavente, Xiuqing Guo, Edith Hofer, Shih-Jen Hwang, Sharon M. Lutz, Leo-Pekka Lyytikaeinen, Lotte Slenders, Albert V. Smith, Maggie A. Stanislawski, Jessica van Setten, Quenna Wong, Lisa R. Yanek, Diane M. Becker, Marian Beekman, Matthew J. Budoff, Mary F. Feitosa, Chris Finan, Austin T. Hilliard, Sharon L. R. Kardia, Jason C. Kovacic, Brian G. Kral, Carl D. Langefeld, Lenore J. Launer, Shaista Malik, Firdaus A. A. Mohamed Hoesein, Michal Mokry, Reinhold Schmidt, Jennifer A. Smith, Kent D. Taylor, James G. Terry, Jeroen van der Grond, Joyce van Meurs, Rozemarijn Vliegenthart, Jianzhao Xu, Kendra A. Young, Nuno R. Zilhao, Robert Zweiker, Themistocles L. Assimes, Lewis C. Becker, Daniel Bos, J. Jeffrey Carr, L. Adrienne Cupples, Dominique P. v. de Kleijn, Menno de Winther, Hester M. den Ruijter, Myriam Fornage, Barry I. Freedman, Vilmundur Gudnason, Aroon D. Hingorani, John E. Hokanson, M. Arfan Ikram, Ivana Isgum, David R. Jacobs, Mika Kaehoenen, Leslie A. Lange, Terho Lehtimaeki, Gerard Pasterkamp, Olli T. Raitakari, Helena Schmidt, P. Eline Slagboom, Andre G. Uitterlinden, Meike W. Vernooij, Joshua C. Bis, Nora Franceschini, Bruce M. Psaty, Wendy S. Post, Jerome I. Rotter, Johan L. M. Bjoerkegren, Christopher J. O'Donnell, Lawrence F. Bielak, Patricia A. Peyser, Rajeev Malhotra, Sander W. van der Laan, Clint L. Miller

Summary: This study conducted a large-scale analysis and identified eleven new risk loci for coronary artery calcification (CAC), a measure of subclinical atherosclerosis. These new loci are related to bone mineralization, phosphate catabolism, and hormone metabolic pathways. The findings contribute to a better understanding of the genetic architecture of CAC and provide potential targets for therapeutic interventions.

NATURE GENETICS (2023)

Review Biochemistry & Molecular Biology

Biological and functional multimorbidity-from mechanisms to management

Claudia Langenberg, Aroon D. Hingorani, Christopher J. M. Whitty

Summary: Globally, the number of people with multiple co-occurring diseases is expected to rise in the future, which will have significant implications for various stakeholders. To address this challenge, there needs to be a shift in clinical, educational, and scientific thinking, emphasizing the maintenance of generalist skills alongside specialized medical education and research. Multimorbidity is not uniform, but varies across different factors, such as age, ethnicity, gender, socioeconomic status, and geography. Data-driven research can help quantify the impact of disease co-occurrence and identify common clusters, enabling a more comprehensive understanding of multimorbidity and the provision of efficient and integrated healthcare services for patients.

NATURE MEDICINE (2023)

Article Clinical Neurology

Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity

Mona M. Almramhi, Chris Finan, Catherine S. Storm, Amand F. Schmidt, Demis A. Kia, Rachel Coneys, Sandesh Chopade, Aroon D. Hingorani, Nick W. Wood

Summary: The study suggests that RAC2 is a genetic modifier of MS risk and supports a causal effect of HDL-C on MS risk.

NEUROLOGY (2023)

Article Medicine, General & Internal

HFrEF subphenotypes based on 4210 repeatedly measured circulating proteins are driven by different biological mechanisms

Teun B. Petersen, Marie de Bakker, Folkert W. Asselbergs, Magdalena Harakalova, K. Martijn Akkerhuis, Jasper J. Brugts, Jan van Ramshorst, R. Thomas Lumbers, Rachel M. Ostroff, Peter D. Katsikis, Peter J. van der Spek, Victor A. Umans, Eric Boersma, Dimitris Rizopoulos, Isabella Kardys

Summary: This study identified four distinct subphenotypes of HFrEF based on circulating protein profiles, which had different prognosis and clinical characteristics. These findings can provide insights into the underlying biological mechanisms and personalized treatment opportunities for patients with HFrEF.

EBIOMEDICINE (2023)

Article Medical Informatics

Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study

Valerie Kuan, Spiros Denaxas, Praveetha Patalay, Dorothea Nitsch, Rohini Mathur, Arturo Gonzalez-Izquierdo, Reecha Sofat, Linda Partridge, Amanda Roberts, Ian C. K. Wong, Melanie Hingorani, Nishi Chaturvedi, Harry Hemingway, Aroon Hingorani, MMTRC

Summary: This study provides important data on multimorbidity and comorbidity in diverse populations, highlighting non-random disease associations and patterns. It offers valuable resources for patients, clinicians, researchers, and policymakers to improve prevention, detection, and management of comorbid conditions. The findings also have implications for biomedical research and the development of clinical trials.

LANCET DIGITAL HEALTH (2023)

No Data Available